retatrutide cancer Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C STUDY: Novel “Triagonist” Retatrutide Resolved
Pay in 4 interest-free payments of $6.68 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
























